Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
about
Intrathecal liposomal cytarabine: more friend than foe?Central nervous system disease in hematologic malignancies: historical perspective and practical applications.Liposomal Formulations in Clinical Use: An Updated Review.Clinical pharmacology of encapsulated sustained-release cytarabine.Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing.Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcomeEnhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children.Neuroophthalmological side effects following intrathecal administration of liposomal cytarabine for central nervous system prophylaxis in three adolescents with acute myeloid leukaemia.Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination.Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma.Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement.Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats.Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
P2860
Q33577149-2ADD10C3-12B8-4D2B-8EE7-DB3D56D65C6CQ33585849-7170268F-1BFF-41C3-BC18-3605A609DBBDQ33850427-C08CE0D5-D8EB-4789-912F-9E275D9AAE4BQ34072145-AC458BA8-115C-4948-BA06-5506727243E0Q34102628-0C0D1346-315A-496F-9469-404795CC0981Q34108043-51A2635F-92BC-43FC-813E-5C1AA92DDA30Q35799389-4C22593F-5574-4E82-897B-B3D5E6B6803CQ36199725-3E8F47CF-D639-423E-82EA-A8C113177DFCQ36244643-07C5A138-6C90-48F6-979E-B7AE35A155B9Q36394925-D193486B-6460-47BA-A79F-7BD25C957093Q36407441-5DF02464-6E19-476C-BB8B-80557762C21CQ36656404-951E21CA-5057-4D78-B7F4-245D1978E582Q36706248-B469782C-4EFB-4EB4-B4BE-34B492751483Q37621288-461BFC82-7370-4DD3-AE68-F8D2D6B427C3Q39850933-8F84A7C4-89B7-4E4B-97F4-10CF5230A1C4Q43252087-B5E80D37-B70A-4267-AEA4-16888B72FDF1Q46113291-2360A1A8-DF2A-475B-BADB-D242F909B281Q46428501-CDABA6E6-0904-446F-AE67-8022FD496ECCQ47931263-422D9E8C-0759-479C-A7B6-DED902B36B8AQ53449769-EC063C0C-64DA-413F-A579-C3935FBAABCAQ58780721-CA122CE2-0305-40D3-9C77-47DCEFBA4C2A
P2860
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@en
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@nl
type
label
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@en
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@nl
prefLabel
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@en
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@nl
P2093
P1433
P1476
Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases.
@en
P2093
P304
P356
10.1001/ARCHNEUR.1995.00540330094020
P577
1995-09-01T00:00:00Z